KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia.

Saved in:
Bibliographic Details
Title: KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia.
Authors: Kwon HJ; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea., Shin JE; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea., Khan A; Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Park SY; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea., Kim J; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea., Lee JY; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Lee D; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Lee S; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Im CY; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Moon H; Daegu-Gyeongbuk Medical Innovation Foundation, New Drug Development Center, Daegu, 41061, Republic of Korea., Han YR; Department of Chemistry, College of Science and Technology, Duksung Women'S University, Seoul, 01369, Republic of Korea., Tamai M; Department of Pediatrics, University of Yamanashi, Chuo, Japan., Akahane K; Department of Pediatrics, University of Yamanashi, Chuo, Japan.; Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Kofu City, Japan., Inukai T; Department of Pediatrics, University of Yamanashi, Chuo, Japan.; Global Leukemia Cell-Line Assembly Network, University of Yamanashi, Kofu City, Japan., Lee W; Department of Chemistry, Sungkyunkwan University, Suwon, 16419, Republic of Korea., Kim H; Brain Science Institute, Korea, Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.; Department of Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea., Kim HN; Brain Science Institute, Korea, Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.; Division of Bio-Medical Science and Technology (KIST School), Korea University of Science and Technology (UST), Seoul, 02792, Republic of Korea.; School of Mechanical Engineering, Yonsei University, Seoul, 03722, Republic of Korea.; Yonsei-KIST Convergence Research Institute, Yonsei University, Seoul, 03722, Republic of Korea., Ahn SM; ImmunoForge, Co. Ltd, Seoul, 08591, Republic of Korea. ahn@immunoforge.com.; Department of Genome Medicine and Science, College of Medicine, Gachon University, Incheon, 21565, Republic of Korea. ahn@immunoforge.com., Park HW; Department of Biochemistry, College of Life Science and Biotechnology, Brain Korea 21 FOUR Program, Yonsei University, Seoul, 03722, Republic of Korea. hwp003@yonsei.ac.kr., Kim DW; Hematology Department, Eulji Medical Center, Eulji University, Uijeongbu-Si, Gyeonggi-Do, Republic of Korea. dwkim@eulji.ac.kr.; Leukemia Omics Research Institute, Eulji University, Uijeongbu‑si, Gyeonggi‑Do, Republic of Korea. dwkim@eulji.ac.kr.
Source: Molecular cancer [Mol Cancer] 2025 Apr 14; Vol. 24 (1), pp. 114. Date of Electronic Publication: 2025 Apr 14.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-4598
DOI:10.1186/s12943-025-02292-z